Strata Critical Medical, Inc. (SRTA) is a small-cap healthcare company focused on time-critical logistics and medical services, including organ transport and transplant clinical support. It was formerly known as Blade Air Mobility and changed its name and ticker in August 2025 after divesting its passenger operations to Joby Aviation. Four sell-side analysts currently provide price targets on the stock, and the average comes to about $9.56, which I round to a central target of $9.50. The individual targets range widely from $8.00 to $12.75, and coverage remains uniformly bullish. Craig-Hallum and B. Riley both started with Buy ratings and $8.00 targets in March 2026, Lake Street has kept a Buy rating with targets in the $8.00-to-$9.50 zone, and Ladenburg Thalmann holds the highest objective near $12.75 after multiple increases through 2026. The reasoning is consistent across firms, centering on the company’s position in organ-transplant logistics, the $124 million Keystone Perfusion Services acquisition funded by its cash reserves, and management’s 2026 revenue guidance of $255 million to $270 million. Differences in targets mainly reflect varying assumptions on margin expansion, integration success, and the timeline to sustained profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Shares trade near $4.72, giving the company a market capitalization of roughly $418 million. From that level, reaching the $9.50 central target would require an increase of approximately 100%, which is a very large move over a 12-month research horizon. The path would need to be supported by fundamentals rather than valuation alone. The company is expanding revenue quickly and has reaffirmed its fiscal 2026 guidance, yet it remains unprofitable with negative EPS over the trailing twelve months. Because the stock lacks a meaningful P/E anchor today, investor support hinges on showing that the combined logistics and clinical businesses can scale margins and turn cash-flow positive, which is exactly what the higher analyst targets assume.
Over the past year, the shares have traded in a broad range from roughly $2.55 to about $6.50. The $6.50 area represents a meaningful resistance level, as it marks the prior 52-week high and sits roughly 38% above the current price. Below, the $4.00 level has acted as a support zone. Reaching $9.50 would require not only breaking above the prior high near $6.50 but extending well beyond it, meaning the stock would need to establish new all-time-high territory on sustained buying interest.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms may update them at any time. Investors should monitor quarterly results and the November earnings report, progress on integrating Keystone, updates to full-year guidance, and any analyst target revisions following earnings. For a stock valued primarily on future growth, the most important signals are revenue momentum, gross-margin trends, and the path toward profitability rather than short-term price movement. From what I see, this is important because execution will ultimately determine whether the targets hold.
I often use Tickeron’s AI Daily Buy/Sell Signals as part of my routine to monitor stocks like this one. The tool applies artificial intelligence to track thousands of equities and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical patterns. It helps me spot changes in trend more efficiently than manual reviews alone, especially when following names with wide analyst target ranges and upcoming catalysts.
The question of whether SRTA can reach $9.50 is best understood as a test of execution rather than valuation. The central target is the rounded mean of four analyst targets that average about $9.56, within a wide $8.00-to-$12.75 range, and it implies roughly a 100% move from the current price near $4.72. The bull case rests on organ-transplant logistics demand, the Keystone acquisition, and strong revenue guidance, while the bear case centers on continued losses, a rich revenue multiple, and integration risk. Analyst agreement on the "Strong Buy" rating is broad, but the wide spread between the low and high targets signals genuine uncertainty about how quickly margins will improve. Investors should focus next on earnings, guidance, margin progress, and any analyst revisions rather than treating the average target as a promise.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
SRTA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 43 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.
The 10-day RSI Indicator for SRTA moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 30 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRTA as a result. In 60 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
SRTA moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for SRTA moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SRTA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for SRTA crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +15.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTA advanced for three days, in 203 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 146 of 195 cases where SRTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.761) is normal, around the industry mean (204.532). P/E Ratio (11.347) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (1.730) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. SRTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a blank check company, which formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry HospitalNursingManagement